Novartis Pharmaceuticals
This is a Phase IIIb, multicenter, two-arm, randomized, double-blind, parallel group study to evaluate the efficacy and safety of zigakibart + atrasentan compared to zigakibart + placebo in patients with primary IgAN at risk of disease progression.
The study includes a 52-week double-blind treatment period and a 52-week open-label extension (OLE): * Double-blind treatment period: Participants will receive zigakibart and either atrasentan or matching placebo. The purpose is to evaluate if zigakibart + atrasentan demonstrates increased efficacy in reducing proteinuria and delaying progression of disease compared to zigakibart + placebo. It also aims to evaluate the safety and tolerability of zigakibart + atrasentan. * OLE: Participants will receive zigakibart and atrasentan. The purpose is to provide study participants with the opportunit…
Inclusion Criteria: * Aged ≥ 18 years at the time of signing the informed consent, prior to initiation of any study specific activities/procedures * Biopsy-proven IgAN diagnosed within the past 10 years prior to Screening, that, in the opinion of the Investigator, is not due to secondary causes. If a biopsy report within 10 years is not available, re-biopsy may be performed locally during Screening. * eGFR ≥ 30 mL/min/1.73m2 by a central laboratory at Screening, calculated using serum creatinine based on the 2021 CKD-EPI equation (Inker et al 2021) * UPCR ≥ 0.7 g/g (700 mg/g), as measured fro…
Solution for injection via PFS-NSD
Tablet
Tablet